Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling

  title={Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling},
  author={Christoforos Thomas and Anders M. Strom and Karolina Lindberg and Jan-{\AA}ke Gustafsson},
  journal={Breast Cancer Research and Treatment},
Estrogen receptor beta (ERβ) inhibits proliferation in different cellular systems by regulating components of the cell cycle machinery. Eukaryotic cells respond to DNA damage by arresting in G1, S, or G2 phases of the cell cycle to initiate DNA repair. Most tumor cells due to disruptions in the p53-dependent G1 pathway are dependent on S-phase and G2/M checkpoints to maintain genomic integrity in response to DNA damage. We report that induction of ERβ expression causes abrogation of the S-phase… 

ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response

Upregulation of ERβ1 increases the sensitivity of NSCLC cells to treatment with doxorubicin and etoposide and supports the potential predictive and therapeutic value of the receptor in clinical management of the disease.

Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways

Mechanical studies showed that ERβ plays an important role in homologous recombination (HR) mediated repair and ERβ reduced expression and activation of ATM upon DNA damage and the evidence is provided that ER β is required for optimal chemotherapy induced DNA damage response and apoptosis in GBM cells.

Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers

The hypothesis that estrogen receptor signaling converges to suppress effective DNA repair and apoptosis in favor of proliferation is put forward in hormone-dependent breast cancer as it will affect processing of estrogen-induced DNA damage, as well as other genotoxic insults.

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function

The results suggest a collaboration of ERβ and p53 tumor suppressor activity in breast cancer cells that indicates the importance of ligand-regulated ERβ as a tool to target p53 activity and improve the clinical management of resistant disease.

The p53-estrogen receptor loop in cancer.

This review will summarize the current body of knowledge on p53, ERα and ERβ in cancer and discuss the relationship between p53 and ERs at both the molecular and clinical levels.

Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.

In conclusion, ERβ5 interacts with Bcl2L12 and functions in a novel estrogen-independent molecular pathway that promotes chemotherapeutic Agent-Induced in vitro apoptosis of BCa cell lines.

Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis

Somatic loss of ERβ significantly accelerated formation of p53-deficient mammary tumors and resulted in the development of less differentiated carcinomas with stronger spindle cell morphology and decreased expression of luminal epithelial markers.

ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway

Upregulation of wild-type ERβ (ERβ1) or treatment with ERβ agonists enhanced apoptosis in breast cancer cells in the presence of pharmacological inducers of EnR stress, suggesting that the ability of ERβ1 to target the UPR may offer alternative treatment strategies for breast cancer.

ERβ Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling

It is demonstrated that ERβ1 decreases the survival of NSCLC cells by regulating oncogenic RAS signaling and downregulation of EGFR and inactivation of RAS and the downstream components ERK1/2 were found to be involved in the ER β1-induced apoptosis.

Roles of Estrogens in Prostate Cancer Development via the Modulation of DNA-Repair System

The function of DNA repair molecules is reviewed at a viewpoint of prostate carcinogenesis and of lifestyle related DNA damages, providing an understanding on the molecular mechanisms by which estrogen may employ their action on the regulation of prostate cancer.



BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.

DNA MMR processing, as measured by the number of 6-TG-induced DNA strand breaks using an alkaline comet assay and by levels of iododeoxyuridine-DNA incorporation, is independent of BRCA1, suggesting the involvement of B RCA1 in the G(2)-M checkpoint response to 6- TG but not in the subsequent excision processing of 5-TG mispairs by MMR.

Participation of p53 protein in the cellular response to DNA damage.

A role for the wild-type p53 protein in the inhibition of DNA synthesis that follows DNA damage is suggested and a new mechanism for how the loss of wild- type p53 might contribute to tumorigenesis is suggested.

Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest

It is demonstrated that ERβ-selective estrogens may lack breast cancer promoting properties exhibited by estrogens in hormone replacement regimens and may be useful for chemoprevention of breast cancer.

Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.

It is demonstrated that ERalpha and ERbeta produce opposite effects in MCF-7 cells on cell proliferation and tumor formation and may be useful for chemoprevention of breast cancer.

Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function

How the G2 DNA damage checkpoint is influenced by p53 status and how the loss of p53 function in cancer cells can be exploited to enhance the cytotoxicity of anti-cancer agents are detailed.

Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

It is suggested that BRCA1-defective in vivo HBCXs express a molecular scenario predictive of high sensitivity to platinum-derived compounds strongly supporting the rationale for prospective tailored clinical trials in hereditary breast cancer.

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Several additional players in the DNA damage response pathway are cataloged, including ATM, DNA-PK, and the MRN complex, which might be amenable to pharmacological interventions and lead to new approaches to sensitize cancer cells to radio- and chemotherapy.

p53 Mediates Repression of the BRCA2 Promoter and Down-regulation of BRCA2 mRNA and Protein Levels in Response to DNA Damage*

It is demonstrated that adriamycin and mitomycin C, but not other DNA-damaging agents, repress BRCA2 promoter activity in a dose- and time-dependent manner and that the effect is dependent on wild type p53 and p53 mediate repression of the BRC a2 promoter by inhibiting binding of an upstream stimulatory factor protein complex to the promoter.